Multicolor Quantum Dot Tracking Uncovers Phenotypic Rescue of DAT A559V Aberrant Diffusion Upon D2R Antagonism

Area of Science:

• Neuroscience
• Cell Biology
• Pharmacology

Background:

• The human dopamine transporter (DAT) regulates dopamine signaling and its dysfunction is linked to neuropsychiatric disorders.
• DAT's membrane mobility and clustering influence dopamine signaling; a mutant DAT (A559V) exhibits anomalous dopamine efflux (ADE) and altered mobility.
• The D2 dopamine autoreceptor short isoform (D2S) can augment ADE in DAT A559V and potentially form complexes with DAT.

Purpose of the Study:

• To investigate the effect of D2S antagonism on the membrane mobility of DAT and the DAT A559V mutant.
• To determine if D2S antagonism can rescue the aberrant mobility of the DAT A559V mutant.
• To analyze the colocalization and interaction dynamics between DAT and D2S in live cells.

Main Methods:

• Utilized quantum dot (Qdot)-based single-molecule localization microscopy for live-cell imaging.
• Employed single-color Qdot-DAT tracking to assess DAT and DAT A559V membrane mobility.
• Used two-color Qdot tracking to simultaneously monitor DAT and D2S colocalization and diffusion.

Main Results:

• D2S antagonism rescued the aberrant lateral mobility of the DAT A559V mutant, restoring it to wild-type levels.
• The rescued mobility of DAT A559V was independent of CaMKII activity, which is linked to ADE.
• Both wild-type DAT and DAT A559V showed increased colocalization with D2S upon D2S antagonism, without affecting D2S diffusion.

Conclusions:

• D2S antagonism represents a potential therapeutic strategy by rescuing DAT A559V mobility defects.
• D2S antagonism stabilizes DAT-D2S interactions, suggesting confinement within D2S microdomains.
• Targeting D2S offers a novel approach to modulate DAT function and potentially treat related neuropsychiatric conditions.